Investment Rating - The report assigns a "Buy" rating for the company, indicating a favorable outlook compared to the market index [8]. Core Insights - The company specializes in the research, production, and sales of plant extracts, focusing on natural vitamin P compounds such as quercetin, rutin, diosmin, and hesperidin. It has established itself as a standard-setting organization for several products in the industry [1]. - In the first nine months of 2024, the company achieved a revenue of 223.83 million yuan, representing a year-on-year increase of 31.83%. The net profit attributable to shareholders was 19.53 million yuan, up 54.23% year-on-year [5]. - The company reported a gross margin of 20.52% for the first nine months of 2024, an increase of 4.08 percentage points compared to the previous year, and a net margin of 8.60%, up 1.15 percentage points [5]. Financial Summary - Revenue (in million yuan): - 2020: 191.45 - 2021: 300.86 - 2022: 269.44 - 2023: 242.81 - Year-on-year growth: 2021 (+57.14%), 2022 (-10.44%), 2023 (-9.88%) [1] - Net Profit (in million yuan): - 2020: 22.66 - 2021: 41.92 - 2022: 33.66 - 2023: 16.67 - Year-on-year growth: 2021 (+85.00%), 2022 (-19.69%), 2023 (-50.48%) [1] - Gross Margin: - 2020: 24.16% - 2021: 24.30% - 2022: 22.51% - 2023: 16.25% [1] - Return on Equity (ROE): - 2020: 22.68% - 2021: 32.71% - 2022: 12.61% - 2023: 4.26% [1] - Earnings per Share (in yuan): - 2020: 0.30 - 2021: 0.55 - 2022: 0.45 - 2023: 0.22 [1] - Price-to-Earnings Ratio (P/E): - 2020: 7.62 - 2021: 21.97 - 2022: 22.76 - 2023: 64.65 [1] Market Data - As of November 8, 2024, the closing price of the company's stock is 23.75 yuan, with a total share capital of 75.63 million shares and a net asset value of 409.17 million yuan [3].
欧康医药：Q3收入端、利润端同比高速增长